On a day curiously void of bombastic small-cap highlights, it seems appropriate to go for a situation which has classic fundamental merit, in the form of Venture Life (LON:VLG).
On the face of it (pun largely intended), Venture Life has almost everything that matters to a chartist who has just hit the half century mark. The company focuses on developing and retailing products for the ageing population. Given that this is the demographic time bomb which is ticking rather more frantically year by year, the investment argument here is increasingly attractive.
Oral hygiene, nail fungal infections and Rosacea are among the ailments which Venture Life is addressing in its product line currently. As once can imagine, these products and many more like them have will have an increasingly receptive market in years to come. The icing on the cake on the fundamental front was the announcement at the end of January that revenues were up 57% and the group had achieved its maiden EBITDA profit.
The technicals underline the good news in the sense that we are looking at strong progress within a rising trend channel on the daily chart, which has been in place since as long ago as the beginning of last year. The message is that provided we hold above the former post November resistance at 60p, the upside here could be as great as the 2016 resistance line projection at 100p on a 3-6 months timeframe.